|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CHEK2 |
Gene summary for CHEK2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CHEK2 | Gene ID | 11200 |
| Gene name | checkpoint kinase 2 | |
| Gene Alias | CDS1 | |
| Cytomap | 22q12.1 | |
| Gene Type | protein-coding | GO ID | GO:0000075 | UniProtAcc | O96017 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11200 | CHEK2 | LZE24T | Human | Esophagus | ESCC | 3.50e-03 | 1.66e-01 | 0.0596 |
| 11200 | CHEK2 | P2T-E | Human | Esophagus | ESCC | 5.57e-10 | 1.94e-01 | 0.1177 |
| 11200 | CHEK2 | P4T-E | Human | Esophagus | ESCC | 2.28e-16 | 4.07e-01 | 0.1323 |
| 11200 | CHEK2 | P5T-E | Human | Esophagus | ESCC | 1.57e-05 | 1.47e-01 | 0.1327 |
| 11200 | CHEK2 | P8T-E | Human | Esophagus | ESCC | 3.46e-09 | 1.94e-01 | 0.0889 |
| 11200 | CHEK2 | P9T-E | Human | Esophagus | ESCC | 1.55e-13 | 2.77e-01 | 0.1131 |
| 11200 | CHEK2 | P10T-E | Human | Esophagus | ESCC | 1.31e-12 | 2.87e-01 | 0.116 |
| 11200 | CHEK2 | P12T-E | Human | Esophagus | ESCC | 3.95e-04 | 8.70e-02 | 0.1122 |
| 11200 | CHEK2 | P15T-E | Human | Esophagus | ESCC | 1.73e-07 | 2.33e-01 | 0.1149 |
| 11200 | CHEK2 | P16T-E | Human | Esophagus | ESCC | 8.27e-04 | 1.59e-01 | 0.1153 |
| 11200 | CHEK2 | P20T-E | Human | Esophagus | ESCC | 4.51e-10 | 2.66e-01 | 0.1124 |
| 11200 | CHEK2 | P21T-E | Human | Esophagus | ESCC | 4.74e-03 | 9.72e-02 | 0.1617 |
| 11200 | CHEK2 | P22T-E | Human | Esophagus | ESCC | 4.62e-13 | 2.53e-01 | 0.1236 |
| 11200 | CHEK2 | P23T-E | Human | Esophagus | ESCC | 5.89e-10 | 2.91e-01 | 0.108 |
| 11200 | CHEK2 | P24T-E | Human | Esophagus | ESCC | 3.35e-05 | 1.60e-01 | 0.1287 |
| 11200 | CHEK2 | P26T-E | Human | Esophagus | ESCC | 8.62e-12 | 2.80e-01 | 0.1276 |
| 11200 | CHEK2 | P27T-E | Human | Esophagus | ESCC | 8.51e-11 | 2.59e-01 | 0.1055 |
| 11200 | CHEK2 | P28T-E | Human | Esophagus | ESCC | 1.25e-09 | 1.97e-01 | 0.1149 |
| 11200 | CHEK2 | P30T-E | Human | Esophagus | ESCC | 6.43e-16 | 5.40e-01 | 0.137 |
| 11200 | CHEK2 | P31T-E | Human | Esophagus | ESCC | 4.77e-07 | 2.09e-01 | 0.1251 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0097193111 | Esophagus | ESCC | intrinsic apoptotic signaling pathway | 222/8552 | 288/18723 | 5.87e-28 | 2.02e-25 | 222 |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:0042176111 | Esophagus | ESCC | regulation of protein catabolic process | 280/8552 | 391/18723 | 8.65e-26 | 2.39e-23 | 280 |
| GO:0031647111 | Esophagus | ESCC | regulation of protein stability | 223/8552 | 298/18723 | 5.76e-25 | 1.52e-22 | 223 |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:0050821111 | Esophagus | ESCC | protein stabilization | 140/8552 | 191/18723 | 6.50e-15 | 3.61e-13 | 140 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:0072331111 | Esophagus | ESCC | signal transduction by p53 class mediator | 121/8552 | 163/18723 | 9.61e-14 | 4.69e-12 | 121 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:001021217 | Esophagus | ESCC | response to ionizing radiation | 110/8552 | 148/18723 | 1.11e-12 | 4.78e-11 | 110 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:0008630110 | Esophagus | ESCC | intrinsic apoptotic signaling pathway in response to DNA damage | 78/8552 | 99/18723 | 1.43e-11 | 5.08e-10 | 78 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:000931419 | Esophagus | ESCC | response to radiation | 277/8552 | 456/18723 | 4.42e-11 | 1.43e-09 | 277 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:00000754 | Esophagus | ESCC | cell cycle checkpoint | 117/8552 | 169/18723 | 4.47e-10 | 1.17e-08 | 117 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0411023 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa05166211 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa0411524 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
| hsa0421829 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| hsa0411033 | Esophagus | ESCC | Cell cycle | 126/4205 | 157/8465 | 1.34e-15 | 5.60e-14 | 2.87e-14 | 126 |
| hsa05166310 | Esophagus | ESCC | Human T-cell leukemia virus 1 infection | 164/4205 | 222/8465 | 8.13e-14 | 2.09e-12 | 1.07e-12 | 164 |
| hsa0411534 | Esophagus | ESCC | p53 signaling pathway | 65/4205 | 74/8465 | 3.88e-12 | 6.50e-11 | 3.33e-11 | 65 |
| hsa0421838 | Esophagus | ESCC | Cellular senescence | 119/4205 | 156/8465 | 5.89e-12 | 9.40e-11 | 4.81e-11 | 119 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CHEK2 | SNV | Missense_Mutation | c.1051N>C | p.Glu351Gln | p.E351Q | O96017 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| CHEK2 | SNV | Missense_Mutation | rs886041172 | c.1315N>G | p.Leu439Val | p.L439V | O96017 | protein_coding | deleterious(0.01) | benign(0.073) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| CHEK2 | SNV | Missense_Mutation | c.956T>A | p.Ile319Asn | p.I319N | O96017 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AC-A8OP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CHEK2 | SNV | Missense_Mutation | rs587781563 | c.738T>G | p.Asp246Glu | p.D246E | O96017 | protein_coding | tolerated(0.06) | benign(0.395) | TCGA-BH-A0AV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
| CHEK2 | SNV | Missense_Mutation | novel | c.229N>C | p.Asp77His | p.D77H | O96017 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.999) | TCGA-OL-A66K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHEK2 | SNV | Missense_Mutation | c.1045N>T | p.Gly349Trp | p.G349W | O96017 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A4BA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
| CHEK2 | SNV | Missense_Mutation | novel | c.1248N>C | p.Lys416Asn | p.K416N | O96017 | protein_coding | deleterious(0) | possibly_damaging(0.555) | TCGA-PN-A8MA-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
| CHEK2 | SNV | Missense_Mutation | novel | c.158N>T | p.Ser53Phe | p.S53F | O96017 | protein_coding | tolerated_low_confidence(0.06) | probably_damaging(0.994) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CHEK2 | SNV | Missense_Mutation | novel | c.1379T>A | p.Leu460His | p.L460H | O96017 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A8Q9-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| CHEK2 | SNV | Missense_Mutation | c.1204N>A | p.Glu402Lys | p.E402K | O96017 | protein_coding | tolerated(0.41) | benign(0.005) | TCGA-AA-3815-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | 336446935 | PREXASERTIB | |
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | KENPAULLONE | KENPAULLONE | ||
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | 249565724 | ||
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | WITHAFERIN A | WITHAFERIN A | 24079846 | |
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | XL844 | |||
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | 178102613 | ISOGRANULATIMIDE | |
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | inhibitor | 249565819 | ||
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | MLN-8054 | MLN-8054 | ||
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | RG-1530 | RG-1530 | ||
| 11200 | CHEK2 | ENZYME, CLINICALLY ACTIONABLE, SERINE THREONINE KINASE, KINASE, TRANSCRIPTION FACTOR, DRUGGABLE GENOME | CEDIRANIB | CEDIRANIB |
| Page: 1 2 3 4 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |